Uncommon EGFR mutations in lung adenocarcinomas: Clinical features and response to tyrosine kinase inhibitors

Brindel, A., Althakfi, W., Barritault, M., Bringuier, P.-P., Watkin, E., Maury, J.-M., … Brevet, M. (2018). Uncommon EGFR mutations in lung adenocarcinomas: Clinical features and response to tyrosine kinase inhibitors. Annals of Oncology, 29, viii747–viii748. https://doi.org/10.1093/annonc/mdy424.072